Akorn (AKRX) Stock Price, News & Analysis

Company Overview

Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.09 to $0.32
• 52-Week Range: N/A
• Volume: 1.19 million shs
• Average Volume: 9.60 million shs
• Market Capitalization: $3.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AKRX Stock Analysis - Frequently Asked Questions

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) posted its quarterly earnings results on Monday, May, 11th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.45. The firm had revenue of $204.69 million for the quarter, compared to the consensus estimate of $168.90 million. Akorn had a negative net margin of 55.64% and a positive trailing twelve-month return on equity of 8.53%.

What other stocks do shareholders of Akorn own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akorn investors own include Bristol Myers Squibb (BMY), Integrated Device Technology (IDTI), Skechers U.S.A. (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC) and Quantenna Communications (QTNA).

Company Calendar

• Last Earnings: 5/11/2020
• Today: 8/20/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AKRX
• CIK: 3116
• Web: www.akorn.com
• Phone: 847-279-6100
• Fax: N/A
• Employees: 2,227
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$226.77 million
• Net Margins: -55.64%
• Pretax Margin: N/A
• Return on Equity: 8.53%
• Return on Assets: 1.31%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 0.50
• Quick Ratio: 0.32

Sales & Book Value

• Annual Sales: $682.43 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.19
• Book Value: $1.86 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 133,152,000
• Free Float: N/A
• Market Cap: $3.60 million
• Optionable: Optionable
• Beta: 0.95